Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site‐limited. Liquid biopsy represents a minimal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Vrabel, David, Sedlarikova, Lenka, Besse, Lenka, Rihova, Lucie, Bezdekova, Renata, Almasi, Martina, Kubaczkova, Veronika, Brožová, Lucie, Jarkovsky, Jiri, Plonkova, Hana, Jelinek, Tomas, Sandecka, Viera, Stork, Martin, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://ncbi.nlm.nih.gov/pubmed/31763708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13358
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados